Biobetter Botulinum Toxin

About Cytodel

CytoDel is pioneering a novel drug delivery platform using engineered, atoxic recombinant botulinum neurotoxins (rBoTs) to transport therapeutic payloads directly into the neuronal cytoplasm, a previously inaccessible target space. Its lead programs focus on biodefense as a botulism antidote and on developing 'biobetter' neurotoxins for neurological conditions and chronic pain. With an exclusive license from NYU Grossman School of Medicine and completed Series A financing, the company is advancing its preclinical pipeline to address high unmet medical needs in neurology and national security.

Therapeutic Areas